Nafarelin
(FSBTYDWUUWLHBD-UDXTWCDOSA-N)
Structure
- SMILES
- CC(=O)O.OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCN=C(N)N)CC(C)C)Cc1ccc2c(c1)cccc2)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1[nH]cnc1.O
- Molecular Formula:
- C68H89N17O16
- Molecular Weight:
- 1400.540
- Log P:
- 3.8985
- Hydrogen Bond Acceptor:
- 31
- Hydrogen Bond Donor:
- 18
- TPSA:
- 521.16
- CAS Number(s):
- 86220-42-0
Synonym(s)
1.
Nafarelin
2.
Nafarelin Acetate
3.
Nafarelin Acetate, Hydrate
4.
Nafarelin Monoacetate
5.
RS-94991-298
6.
Synarel
7.
RS 94991 298
8.
RS94991298
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 8 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 2 | Headache | FAERS: 7 | US FAERS | |
| 3 | Cerebral Infarction | FAERS: 5 | US FAERS | |
| 4 | Syncope | FAERS: 5 | US FAERS | |
| 5 | Drug dose omission | FAERS: 4 | US FAERS | |
| 6 | Fatigue | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 7 | Amnesia | FAERS: 3 | US FAERS | |
| 8 | Endometrial Hyperplasia | FAERS: 3 | US FAERS | |
| 9 | Feeling abnormal | FAERS: 3 | US FAERS | |
| 10 | Hyperthyroidism | FAERS: 3 | US FAERS | |
| 11 | Respiratory distress | FAERS: 3 | US FAERS | |
| 12 | Visual Impairment | FAERS: 3 | US FAERS | |
| 13 | Abdominal Pain | FAERS: 2 | US FAERS | |
| 14 | Anaphylactoid Reaction | FAERS: 2 | US FAERS | |
| 15 | Arthropathy | FAERS: 2 | US FAERS | |
| 16 | Cerebral vasoconstriction | FAERS: 2 | US FAERS | |
| 17 | Dizziness | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 18 | Drug effective for unapproved indication | FAERS: 2 | US FAERS | |
| 19 | Incorrect dose administered | FAERS: 2 | US FAERS | |
| 20 | Malaise | FAERS: 2 | US FAERS | |
| 21 | Metrorrhagia | FAERS: 2 | US FAERS | |
| 22 | Monoplegia | FAERS: 2 | US FAERS | |
| 23 | Nausea | FAERS: 2 | US FAERS | |
| 24 | Night sweats | FAERS: 2 | US FAERS | |
| 25 | Pain | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 26 | Product quality issue | FAERS: 2 | US FAERS | |
| 27 | Stress | FAERS: 2 | US FAERS | |
| 28 | Thrombotic cerebral infarction | FAERS: 2 | US FAERS | |
| 29 | Vomiting | FAERS: 2 | US FAERS | |
| 30 | Abdominal discomfort | FAERS: 1 | US FAERS | |
| 31 | Anti-thyroid antibody positive | FAERS: 1 | US FAERS | |
| 32 | Ataxia | FAERS: 1 | US FAERS | |
| 33 | Back Pain | FAERS: 1 | US FAERS | |
| 34 | Blood blister | FAERS: 1 | US FAERS | |
| 35 | Bone pain | FAERS: 1 | US FAERS | |
| 36 | Carbohydrate antigen 19-9 increased | FAERS: 1 | US FAERS | |
| 37 | Chills | FAERS: 1 | US FAERS | |
| 38 | Cleft Palate | FAERS: 1 | US FAERS | |
| 39 | Constipation | FAERS: 1 | US FAERS | |
| 40 | Cyst | FAERS: 1 | US FAERS | |
| 41 | Deafness Neurosensory | FAERS: 1 | US FAERS | |
| 42 | Drug exposure before pregnancy | FAERS: 1 | US FAERS | |
| 43 | Drug exposure during pregnancy | FAERS: 1 | US FAERS | |
| 44 | Drug toxicity | FAERS: 1 | US FAERS | |
| 45 | Dyslalia | FAERS: 1 | US FAERS | |
| 46 | Dysphonia | FAERS: 1 | US FAERS | |
| 47 | Endometrial hypertrophy | FAERS: 1 | US FAERS | |
| 48 | Epistaxis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 49 | Erythema | FAERS: 1 | US FAERS | |
| 50 | Hemiplegia | FAERS: 1 | US FAERS | |
| 51 | Hypersensitivity | FAERS: 1 | US FAERS | |
| 52 | Implant site reaction | FAERS: 1 | US FAERS | |
| 53 | Incorrect product storage | FAERS: 1 | US FAERS | |
| 54 | Lip and/or oral cavity cancer | FAERS: 1 | US FAERS | |
| 55 | Lower respiratory tract infection | FAERS: 1 | US FAERS | |
| 56 | Maternal exposure during pregnancy | FAERS: 1 | US FAERS | |
| 57 | Medication Error | FAERS: 1 | US FAERS | |
| 58 | Memory impairment | FAERS: 1 | US FAERS | |
| 59 | Menstrual discomfort | FAERS: 1 | US FAERS | |
| 60 | Mood swings | FAERS: 1 | US FAERS | |
| 61 | Multiple Sclerosis | FAERS: 1 | US FAERS | |
| 62 | Musculoskeletal stiffness | FAERS: 1 | US FAERS | |
| 63 | Nasal discomfort | FAERS: 1 | US FAERS | |
| 64 | Neurodermatitis | FAERS: 1 | US FAERS | |
| 65 | Oligohydramnios | FAERS: 1 | US FAERS | |
| 66 | Osteoporosis | FAERS: 1 | US FAERS | |
| 67 | Palpitations | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 68 | Peripheral swelling | FAERS: 1 | US FAERS | |
| 69 | Polymenorrhagia | FAERS: 1 | US FAERS | |
| 70 | Posterior reversible encephalopathy syndrome | FAERS: 1 | US FAERS | |
| 71 | Product use in unapproved indication | FAERS: 1 | US FAERS | |
| 72 | Product use issue | FAERS: 1 | US FAERS | |
| 73 | Progesterone decreased | FAERS: 1 | US FAERS | |
| 74 | Sneezing | FAERS: 1 | US FAERS | |
| 75 | Somnolence | FAERS: 1 | US FAERS | |
| 76 | Stillbirth | FAERS: 1 | US FAERS | |
| 77 | Swelling | FAERS: 1 | US FAERS | |
| 78 | Thrombocytopenic purpura | FAERS: 1 | US FAERS | |
| 79 | Urticaria | FAERS: 1 | US FAERS | |
| 80 | Vaginal Discharge | FAERS: 1 | US FAERS | |
| 81 | Weight decreased | FAERS: 1 | US FAERS | |
| 82 | White blood cell count decreased | FAERS: 1 | US FAERS | |
| 83 | Asthenia | Canada Vigilance: 1 | Canada Vigilance | |
| 84 | Chest Pain | Canada Vigilance: 1 | Canada Vigilance | |
| 85 | Deep Vein Thrombosis | Canada Vigilance: 1 | Canada Vigilance | |
| 86 | Dyspepsia | Canada Vigilance: 1 | Canada Vigilance | |
| 87 | Flushing | Canada Vigilance: 1 | Canada Vigilance | |
| 88 | Hypotension | Canada Vigilance: 1 | Canada Vigilance | |
| 89 | Nervousness | Canada Vigilance: 1 | Canada Vigilance | |
| 90 | Therapeutic product effect decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 91 | Tinnitus | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.